TAT-Gap19

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Cx43 hemichannel blocker (IC50 ~7 μM). No significant affinity for gap junctions or Panx1 channels. N-terminal transactivator of transcription (TAT) motif promotes membrane permeability and increases inhibitory effect of Gap19. Active in vivo. Brain penetrant.

Cx43 hemichannel blocker (IC50 ~7 μM). No significant affinity for gap junctions or Panx1 channels. N-terminal transactivator of transcription (TAT) motif promotes membrane permeability and increases inhibitory effect of Gap19. Active in vivo. Brain penetrant.

——

A single injection of TAT-Gap19 (i.v. via the tail vein; 55 mg/kg) produces significant immune signal in the brain 24 h later in 4 months old C57Bl6 male mice. TAT-Gap19 (1 mg/kg/day; an osmotic pump implanted in the peritoneal cavity; Two weeks) shows significantly decreased collagen deposition, as well as lowed amounts of α-SMA-positive cells area in mice subjected to treatment with 100-200 mg thioacetamide (TAA)/kg body weight for eight weeks.

——

Cytoskeleton/Cell Adhesion Molecules

Gap Junction Protein

——

——

——

1507930-54-2

2703.28

C119H212N46O26

>98% (HPLC)

water:1 mg/mL

[H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years